Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer

Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis

“…The incidence of grade 1-4 and grade 3-4 colitis was 0.2% and 0.0%, respectively. The current recommended dose of 480 mg Q4W was part of the intervention of eight studies [24][25][26][27][28][29][30][31] (Suppl. Table 3); however, data for this regimen could not be extracted as these studies included various doses of nivolumab and reported the combined toxicity.…”

Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series

“… 19 , 20 Additionally, a recent phase I trial of patients with ES-SCLC treated with cTRT and subsequent immunotherapy with ipilimumab and nivolumab demonstrated a toxicity profile consistent with the known toxicity rates of ipilimumab and nivolumab, suggesting that cTRT did not increase toxicity. 21 Our current data suggest a favorable safety profile of cTRT after chemoimmunotherapy with atezolizumab for patients with ES-SCLC. Given the overall low rate of toxicity, further prospective studies are warranted to characterize the efficacy of the addition of cTRT to first-line chemoimmunotherapy with atezolizumab.…”

Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer

“…Nevertheless, the exact association between OS and cTRT could not be predicted precisely due to the study's retrospective nature and the low number of included patients (Table 1) [5]. Similar toxicity profiles were reported in a recent prospective single-arm phase 1/2 study [27]. In this study, the researchers assessed the efficacy of cTRT (30 Gy in 10 fractions) after ipiliumab and nivolumab therapy, and found that the OS rate at 12-months was 48%.…”

“…In this study, the researchers assessed the efficacy of cTRT (30 Gy in 10 fractions) after ipiliumab and nivolumab therapy, and found that the OS rate at 12-months was 48%. However, these promising results are slightly overshadowed by the relatively small sample size (n ¼ 21; Table 1) [27]. Lastly, it is worth mentioning that in a retrospective study of 33 patients, Galuba et al [16] also found that the rate of adverse events did not differ significantly between patients receiving both atezolizumab immunotherapy and TRT, and patients receiving TRT solely (Table 1).…”